# Executive Experimentation Decision Memo
## E-Commerce Landing Page Optimization A/B Test
**Author:** Lead Data Scientist (Experimentation Platform)  
**Status:** COMPLETE & CONCLUDED  
**Primary Metric:** Checkout Conversion Rate  
**Target Alpha:** 0.05 (95% Confidence Level)  

---

## 1. Executive Summary & Launch Recommendation

> ### **FINAL DECISION: RETAIN CONTROL VARIANT (DO NOT SHIP)**
> **The new landing page failed to demonstrate statistical superiority over the existing control experience.**  
> - **Observed Conversion Lift:** **-1.31%** (Control: **12.04%** vs. Treatment: **11.88%**)
> - **Frequentist Hypothesis Test:** $p = 0.1899$ (Not statistically significant at $\alpha = 0.05$)
> - **95% Confidence Interval for Lift:** $[-0.39\%, +0.08\%]$ (Spans zero)
> - **Bayesian Posterior Probability:** Only **9.4%** chance that the treatment is superior.
> - **Expected Business Risk:** Deploying Treatment carries a **16.4 bps** expected conversion penalty.
> - **Recommendation:** **Discard variant**. Do not allocate engineering resources to ship `new_page`. Re-evaluate UX friction hypotheses in the funnel.

---

## 2. Data Integrity & Randomization Audit

Before conducting statistical inferences, data sanitization and randomization checks were strictly enforced:

| Integrity Check | Target / Expected | Observed Metric | Audit Status |
|---|---|---|---|
| **Raw Sample Size** | Full event logs | 294,478 rows | Logged |
| **Contaminated Records** | 0 mismatches | 3,893 purged | Fixed |
| **Deduplicated User Exposures** | 1 exposure per user | 1 purged | Fixed |
| **Clean Analyzed Sample** | High power volume | 290,584 users | Verified |
| **Sample Ratio Mismatch (SRM)** | $\chi^2$ goodness-of-fit $p \ge 0.01$ | $\chi^2 = 0.0045, p = 0.9468$ | **PASSED (No Traffic Bias)** |
| **Control Group Traffic** | 50.0% allocation | 145,274 (49.99%) | Balanced |
| **Treatment Group Traffic** | 50.0% allocation | 145,310 (50.01%) | Balanced |

---

## 3. Frequentist Statistical Evidence

- **Test Mechanism:** Two-Proportion Pooled Z-Test
- **Control Baseline:** 12.04% (145,274 visitors)
- **Treatment Observed:** 11.88% (145,310 visitors)
- **Difference in Proportions:** -0.00158 (-1.31% relative)
- **Test Statistic ($Z$):** -1.3109
- **P-Value:** **0.1899**
- **Cohen's $h$ Effect Size:** -0.0049 (*negligible*)
- **Practical Significance Threshold (MDE):** 0.005

---

## 4. Bayesian Evidence & Decision Theory

- **Prior Specification:** $\text{Beta}(\alpha_0=1.0, \beta_0=1.0)$ (Uninformative Uniform Prior)
- **Control Posterior:** $\text{Beta}(\alpha=17490, \beta=127786)$ (Mean = 12.04%)
- **Treatment Posterior:** $\text{Beta}(\alpha=17265, \beta=128047)$ (Mean = 11.88%)
- **$P(\text{Treatment} > \text{Control})$:** **9.4%**
- **95% Credible Interval (HDI):** $[-0.40\%, +0.08\%]$
- **Expected Loss (Risk of choosing Treatment):** 0.001638
- **Expected Loss (Risk of choosing Control):** 0.000053
- **ROPE Probability ($|\text{Lift}| < 0.1\%$):** 29.8%

---

## 5. Sequential Monitoring & Peeking Audit

- **Days Monitored:** 23 sequential daily evaluations
- **Alpha Spending Function:** O'Brien-Fleming boundary
- **Early Stopping Triggered:** **False**
- **Peeking Diagnosis:** O'Brien-Fleming alpha-spending safely bounds total Type I error at exactly alpha=0.05.

---

## 6. Subgroup / Heterogeneous Treatment Effects

Decomposition across geography:

| Country | Traffic Share | Control Rate | Treatment Rate | Observed Lift | P-Value | Significance |
|---|---|---|---|---|---|---|
| **US** | 70.1% | 12.06% | 11.85% | -1.79% | 0.1323 | Not Significant |
| **UK** | 24.9% | 12.00% | 12.12% | +0.96% | 0.6349 | Not Significant |
| **CA** | 5.0% | 11.88% | 11.19% | -5.79% | 0.1947 | Not Significant |

- **Simpson's Paradox Detected:** **False**
- **Synthesis:** Homogeneous performance across subgroups.

---

## 7. Next Steps & Post-Mortem Action Items
1. **Archive Redesign Asset:** Do not roll out `new_page` to production.
2. **Qualitative User Research:** Review session recordings to understand why users converted slightly less on `new_page`.
3. **Formulate Next Iteration:** Develop new hypotheses focusing on simplified checkout form fields rather than full-page redesign.
